We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+0.97%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$435M
AUM Growth
-$39.5M
Cap. Flow
-$37.1M
Cap. Flow %
-8.54%
Top 10 Hldgs %
95.72%
Holding
17
New
–
Increased
2
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$8.64M
2
MDCO
Medicines Co
MDCO
+$4.09M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$18.9M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$15.7M
3
DGX icon
Quest Diagnostics
DGX
+$14.8M
4
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$462K

Sector Composition

Rank Sector Weight
1 Healthcare 89.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARIA
1
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$106M 24.45%
12,850,000
– –
ABBV icon
2
AbbVie
ABBV
$443B
$106M 24.43%
1,580,000
– –
DGX icon
3
Quest Diagnostics
DGX
$25.7B
$41.7M 9.6%
575,000
-200,000
-26% -$14.8M
MDCO
4
DELISTED
Medicines Co
MDCO
$39M 8.97%
1,361,900
+146,800
+12% +$4.09M
AEGR
5
DELISTED
Aegerion Pharmaceuticals
AEGR
$38.6M 8.89%
2,036,829
+399,374
+24% +$8.64M
AMGN icon
6
Amgen
AMGN
$208B
$30.7M 7.07%
200,000
-118,000
-37% -$18.9M
MRK icon
7
Merck
MRK
$322B
$22.8M 5.24%
419,200
– –
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.5M 2.65%
360,000
– –
SEEL
9
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$11.2M 2.57%
6
– –
RPRX
10
DELISTED
Repros Therapeutics Inc.
RPRX
$8.1M 1.86%
1,132,367
– –
VVUS
11
DELISTED
Vivus Inc
VVUS
$6.08M 1.4%
257,394
– –
KIN
12
DELISTED
Kindred Biosciences, Inc.
KIN
$4.7M 1.08%
689,091
– –
AVEO
13
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$4.03M 0.93%
231,376
-25,700
-10% -$462K
ANIP icon
14
ANI Pharmaceuticals
ANIP
$1.8B
$1.92M 0.44%
31,000
– –
GYRE icon
15
Gyre Therapeutics
GYRE
$641M
$1.76M 0.4%
800
– –
CARM
16
DELISTED
Carisma Therapeutics
CARM
$116K 0.03%
2,060
– –
AVDL
17
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-875,000
Closed -$15.7M

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sarissa Capital Management held 17 positions worth $435M, down 8.3% from $474M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Sarissa Capital Management withdrew a net $37.1M in Q2 2015, closing 1 position and reducing 3 holdings. Its most notable exit was Avadel Pharmaceuticals, an estimated $15.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier.

Against the trend, Sarissa Capital Management added an estimated $8.64M to Aegerion Pharmaceuticals.

  • Sarissa Capital Management added most to Aegerion Pharmaceuticals in Q2 2015, an estimated $8.64M increase.
  • Sarissa Capital Management's biggest Q2 2015 reduction was Amgen, cutting an estimated $18.9M.
  • Sarissa Capital Management fully exited Avadel Pharmaceuticals in Q2 2015, selling an estimated $15.7M.
  • Sarissa Capital Management's ten largest holdings make up 96% of its $435M portfolio in Q2 2015.
  • Sarissa Capital Management opened 0 new positions and closed 1 in Q2 2015.
  • Sarissa Capital Management's portfolio value fell 8.3% quarter-over-quarter to $435M.

Based on Sarissa Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.